Exhibit 99.1 HERTZ LOGS BEST QUARTERLY RESULTS IN NEARLY TWO YEARS, DRIVEN BY HALF A BILLION DOLLAR PROFITABILITY IMPROVEMENT ------------------------------------------------------------------------------------------------------------------ "Our transformation is taking hold," said Gil West, CEO of Hertz. "Through smarter fleet management, improved utilization, enhanced customer experience, disciplined cost control, and the hard work of our people, it's clear our strategy is working. We're building a strong ...

Exhibit 99.1 CONTACT: Rob Seelig (603) 640-2212 WHITE MOUNTAINS REPORTS SECOND QUARTER RESULTS HAMILTON, Bermuda (August 7, 2025) - White Mountains Insurance Group, Ltd. (NYSE: WTM) reported book value per share of $1,804 as of June 30, 2025, an increase of 3% for both the second quarter of 2025 and the first six months of 2025, including dividends. Manning Rountree, CEO, commented, "BVPS was up 3% in the quarter. We had sound results at our operating companies and good investment returns. Ark produced an 8 ...

Exhibit 99.1 Perimeter Solutions Reports Second Quarter 2025 Financial Results August 7, 2025 Second quarter Net Loss of $32.2M and Adjusted Net Income of $57.1M Continued value driver execution and normalized fire activity drove second quarter Adjusted EBITDA of $91.3M Second quarter Loss Per Diluted Share of $0.22 and Adjusted Earnings Per Diluted Share of $0.39 Clayton, Missouri, August 7, 2025 – Perimeter Solutions, Inc. (NYSE: PRM) ("Perimeter," "Perimeter Solutions," or the "Company"), a leading globa ...

PART I. FINANCIAL INFORMATION [Condensed Consolidated Financial Statements (Unaudited)](index=4&type=section&id=ITEM%201.%20Condensed%20Consolidated%20Financial%20Statements%20%28Unaudited%29) Presents unaudited condensed consolidated financial statements for Hertz Global Holdings, including balance sheets, income, cash flows, and detailed notes [Financial Statements - Hertz Global Holdings, Inc.](index=5&type=section&id=Financial%20Statements%20-%20Hertz%20Global%20Holdings%2C%20Inc%2E) Hertz Global Holdings reported decreased Q2 2025 revenue but a narrowed net loss, with assets increasing and equity turning to a deficit Hertz Global Holdings, Inc. - Key Financials (Q2 2025 vs Q2 2024) | Metric | Q2 2025 (in millions) | Q2 2024 (in millions) | | :--- | :--- | :--- | | **Revenues** | $2,185 | $2,353 | | **Net Loss** | $(294) | $(865) | | **Basic and Diluted EPS** | $(0.95) | $(2.82) | Hertz Global Holdings, Inc. - Balance Sheet Summary | Metric | June 30, 2025 (in millions) | Dec 31, 2024 (in millions) | | :--- | :--- | :--- | | Total Assets | $23,083 | $21,802 | | Total Liabilities | $23,587 | $21,649 | | Total Stockholders' Equity (Deficit) | $(504) | $153 | - For the six months ended June 30, 2025, net cash provided by operating activities was **$597 million**, a decrease from **$916 million** in the prior year period. Net cash used in investing activities improved to **$1.56 billion** from **$2.78 billion**[26](index=26&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=17&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail an **$89 million** gain from sale-leaseback, improved vehicle disposal gains, total debt increase to **$17.6 billion**, and a **$330 million** litigation accrual - In June 2025, the company sold and leased back certain properties, recognizing a pre-tax gain of **$89 million**. An additional sale-leaseback in July 2025 is expected to generate a pre-tax gain between **$35 million** and **$40 million**[56](index=56&type=chunk)[57](index=57&type=chunk) - The company recorded a net gain on disposal of revenue earning vehicles of **$38 million** in Q2 2025, a significant improvement from a **$182 million** loss in Q2 2024. This was a primary driver of improved profitability[60](index=60&type=chunk) Total Debt Summary | Debt Category | June 30, 2025 (in millions) | Dec 31, 2024 (in millions) | | :--- | :--- | :--- | | Non-Vehicle Debt | $5,434 | $5,104 | | Vehicle Debt | $12,202 | $11,231 | | **Total Debt** | **$17,636** | **$16,335** | - The company has accrued approximately **$330 million** for litigation related to make-whole premiums and post-petition interest on Unsecured Notes following an adverse appellate court ruling. The company is seeking a review by the U.S. Supreme Court[154](index=154&type=chunk) [Segment Information](index=39&type=section&id=Segment%20Information) Both operating segments improved profitability year-over-year, with Americas RAC Adjusted EBITDA swinging to **$42 million** profit and International RAC also turning positive, driven by lower vehicle depreciation Segment Performance (Three Months Ended June 30) | Segment | Revenues 2025 (in millions) | Revenues 2024 (in millions) | Adjusted EBITDA 2025 (in millions) | Adjusted EBITDA 2024 (in millions) | | :--- | :--- | :--- | :--- | :--- | | Americas RAC | $1,738 | $1,928 | $42 | $(403) | | International RAC | $447 | $425 | $42 | $(6) | | **Total** | **$2,185** | **$2,353** | **$84** | **$(409)** | [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=46&type=section&id=ITEM%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) MD&A discusses Q2 2025 financial results, highlighting improved profitability despite revenue decline, primarily due to reduced vehicle depreciation, and details liquidity, capital resources, and debt financing [Consolidated Results of Operations](index=50&type=section&id=Consolidated%20Results%20of%20Operations) Q2 2025 consolidated revenues decreased by **7%** to **$2.19 billion**, but net loss narrowed significantly to **$179 million**, primarily due to a **60%** (**$620 million**) decrease in vehicle depreciation - The decrease in total revenues for Q2 2025 was primarily due to lower pricing and volume, particularly in the Americas RAC segment[200](index=200&type=chunk) - The key driver of improved profitability was a **$620 million** decrease in net vehicle depreciation expense in Q2 2025 compared to Q2 2024, resulting from a fleet refresh, stronger residual values, and gains on vehicle sales[201](index=201&type=chunk) [Results of Operations by Segment](index=53&type=section&id=Results%20of%20Operations%20by%20Segment) Americas RAC revenue declined **10%** but Adjusted EBITDA improved to **$42 million** profit, driven by **61%** lower depreciation; International RAC revenue grew **5%**, with Adjusted EBITDA turning to **$42 million** profit Americas RAC - Key Metrics (Q2 2025 vs Q2 2024) | Metric | Q2 2025 | Q2 2024 | % Change | | :--- | :--- | :--- | :--- | | Total Revenues | $1,738 M | $1,928 M | (10)% | | Adjusted EBITDA | $42 M | $(403) M | NM | | Total RPD | $56.08 | $59.73 | (6)% | | Depreciation Per Unit Per Month | $248 | $644 | (61)% | International RAC - Key Metrics (Q2 2025 vs Q2 2024) | Metric | Q2 2025 | Q2 2024 | % Change | | :--- | :--- | :--- | :--- | | Total Revenues | $447 M | $425 M | 5% | | Adjusted EBITDA | $42 M | $(6) M | NM | | Vehicle Utilization | 81% | 77% | +4 p.p. | | Depreciation Per Unit Per Month | $261 | $384 | (32)% | [Liquidity and Capital Resources](index=62&type=section&id=Liquidity%20and%20Capital%20Resources) Corporate liquidity was **$1.45 billion** as of June 30, 2025, a decrease from year-end 2024, deemed sufficient for the next twelve months, with recent RCF amendments and new vehicle-backed notes - Corporate liquidity stood at **$1.45 billion** as of June 30, 2025, down from **$1.84 billion** at December 31, 2024[275](index=275&type=chunk) - In May 2025, the company amended its First Lien RCF, extending the maturity of **$1.7 billion** of commitments from June 2026 to March 2028[277](index=277&type=chunk) - Net capital expenditures for revenue earning vehicles for the first six months of 2025 was **$1.65 billion**, a **40%** decrease from **$2.73 billion** in the same period of 2024, driven by higher proceeds from vehicle disposals[306](index=306&type=chunk)[307](index=307&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=73&type=section&id=ITEM%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) No material changes to market risk exposures, including interest rates, foreign currency, and fuel prices, have occurred since the 2024 Form 10-K disclosures - There have been no material changes to the company's market risk disclosures since its Annual Report on Form 10-K for the year ended December 31, 2024[328](index=328&type=chunk) [Controls and Procedures](index=73&type=section&id=ITEM%204.%20Controls%20and%20Procedures) CEO and CFO concluded disclosure controls and procedures were effective, with no material changes to internal control over financial reporting during the quarter - The CEO and CFO concluded that as of June 30, 2025, the company's disclosure controls and procedures were effective[329](index=329&type=chunk)[331](index=331&type=chunk) - No material changes in internal control over financial reporting occurred during the three months ended June 30, 2025[330](index=330&type=chunk)[332](index=332&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=74&type=section&id=ITEM%201.%20Legal%20Proceedings) Refers to Note 12 of the Condensed Consolidated Financial Statements for detailed information on pending legal proceedings - For a description of pending legal proceedings, the report refers to Note 12, "Contingencies and Off-Balance Sheet Commitments," in Part I, Item 1[334](index=334&type=chunk) [Risk Factors](index=74&type=section&id=ITEM%201A.%20Risk%20Factors) No material changes to risk factors have occurred since those disclosed in the company's 2024 Annual Report on Form 10-K - There have been no material changes to the risk factors disclosed in the company's 2024 Form 10-K[335](index=335&type=chunk) [Other Items (Items 2, 3, 5, 6)](index=74&type=section&id=Other%20Items%20%28Items%202%2C%203%2C%205%2C%206%29) Covers standard disclosures, reporting no unregistered equity sales, no defaults on senior securities, no Rule 10b5-1 trading plans by directors/officers, and refers to the Exhibit Index - The company reported no unregistered sales of equity securities or use of proceeds for the period[336](index=336&type=chunk) - No defaults upon senior securities were reported[337](index=337&type=chunk) - No director or officer entered into a Rule 10b5-1 trading arrangement during the quarter ended June 30, 2025[338](index=338&type=chunk)

Cumulus Media Reports Operating Results for the Second Quarter 2025 ATLANTA, GA — August 7, 2025: Cumulus Media Inc. (OTCQB: CMLS) (the "Company," "Cumulus Media," "we," "us," or "our") today announced operating results for the three and six months ended June 30, 2025. Mary G. Berner, President and Chief Executive Officer of Cumulus Media, said, "While the advertising backdrop for legacy media remains challenging, in the quarter we continued to outperform our radio peers, gaining market share across all bro ...

PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights – Last patient dosed in 15 mg/kg cohort of FREEDOM-DM1; on track to report topline data from study in early Q4 2025 – – FREEDOM to conclude with the 15 mg/kg cohort based on splicing and safety data observed to date; clinical sites will begin transitioning to the Phase 2 multiple ascending dose study, FREEDOM2-DM1 – BOSTON— August 7, 2025-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the nex ...

Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _________________________ (Mark one) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39511 _________________________ BURFORD CAPITAL LIMITED (Exact name of registrant as ...

[Overview and Business Highlights](index=1&type=section&id=Overview%20and%20Business%20Highlights) UroGen Pharma achieved a transformative milestone with ZUSDURI™ FDA approval and launch, complementing JELMYTO®'s continued growth and advancing its pipeline [Executive Summary](index=1&type=section&id=Executive%20Summary) UroGen Pharma's Q2 2025 results highlight the transformative FDA approval and commercial launch of ZUSDURI™, establishing the company as a multi-product uro-oncology entity alongside JELMYTO®'s continued growth - The FDA approval of ZUSDURI™ for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) is a **transformative milestone**, establishing UroGen as a multi-product company[3](index=3&type=chunk)[8](index=8&type=chunk) - The company is executing the commercial launch of ZUSDURI™ to address an estimated market opportunity of **over $5 billion**[3](index=3&type=chunk) Q2 2025 Key Metrics Snapshot | Metric | Value | Growth (YoY) | | :--- | :--- | :--- | | JELMYTO® Net Sales | $24.2 million | 11% | | Cash & Marketable Securities | $161.6 million | N/A | [Product Portfolio and Pipeline Update](index=1&type=section&id=Product%20Portfolio%20and%20Pipeline%20Update) UroGen's commercial portfolio expanded with ZUSDURI™'s launch, complementing JELMYTO®'s growth, while the pipeline advances with next-generation formulations and an immuno-oncology candidate [ZUSDURI™ (mitomycin) for intravesical solution](index=1&type=section&id=ZUSDURI%E2%84%A2%20(mitomycin)%20for%20intravesical%20solution) ZUSDURI™ received FDA approval as the first and only medication for recurrent LG-IR-NMIBC, supported by strong Phase 3 and Phase 2b clinical data - On June 12, 2025, ZUSDURI™ (formerly UGN-102) was approved by the FDA, becoming the **first and only approved medication** for adults with recurrent LG-IR-NMIBC[8](index=8&type=chunk) - Updated data from the Phase 3 ENVISION trial demonstrated a **72.2% probability** of patients remaining in complete response at 24 months[8](index=8&type=chunk) - Five-year results from the Phase 2b OPTIMA II trial showed a median duration of response of **approximately 3.5 years**[8](index=8&type=chunk) [JELMYTO® (mitomycin) for pyelocalyceal solution](index=1&type=section&id=JELMYTO%C2%AE%20(mitomycin)%20for%20pyelocalyceal%20solution) JELMYTO® demonstrated 11% year-over-year revenue growth in Q2 2025, driven by increased demand and price favorability, with ongoing real-world data collection JELMYTO® Q2 2025 Performance | Metric | Q2 2025 | Q2 2024 | YoY Growth | | :--- | :--- | :--- | :--- | | Net Product Revenue | $24.2 million | $21.8 million | 11% | - The **11% year-over-year revenue growth** was driven by a **7% increase in underlying demand** and price favorability[8](index=8&type=chunk)[11](index=11&type=chunk) - The uTRACT Registry, a real-world study of JELMYTO®, is ongoing to provide insights into treatment patterns, long-term outcomes, and patient safety[8](index=8&type=chunk) [Pipeline Development](index=1&type=section&id=Pipeline%20Development) UroGen's pipeline advanced with completed enrollment for UGN-103's Phase 3 trial, initiation of UGN-104's Phase 3 study, and completed dose escalation for UGN-301 - **UGN-103 (Next-gen ZUSDURI):** Enrollment is **complete** in the Phase 3 UTOPIA clinical trial for patients with recurrent LG-IR-NMIBC[6](index=6&type=chunk) - **UGN-104 (Next-gen JELMYTO):** A Phase 3 study to evaluate the safety and efficacy of this next-generation product for LG-UTUC has been **initiated**[9](index=9&type=chunk) - **UGN-301 (zalifrelimab):** Enrollment is **complete** in the dose escalation phase for this anti-CTLA4 antibody, showing an acceptable safety profile and observed responses[10](index=10&type=chunk) [Financial Performance](index=2&type=section&id=Financial%20Performance) UroGen's Q2 2025 financial performance reflects increased net loss due to ZUSDURI™ launch preparations and R&D investments, alongside JELMYTO® revenue growth and reaffirmed full-year guidance [Second Quarter 2025 Financial Results](index=2&type=section&id=Second%20Quarter%202025%20Financial%20Results) UroGen reported a wider Q2 2025 net loss of $49.9 million, primarily driven by increased SG&A for ZUSDURI™ launch and higher R&D expenses, despite JELMYTO® revenue growth Q2 2025 Financial Summary (vs. Q2 2024) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | JELMYTO Revenue | $24.2 million | $21.8 million | | R&D Expenses | $18.9 million | $15.4 million | | SG&A Expenses | $43.2 million | $30.1 million | | Net Loss | $49.9 million | $33.4 million | | Net Loss per Share | ($1.05) | ($0.82) | | Cash & Equivalents (End of Period) | $161.6 million | N/A | - The increase in SG&A expenses was primarily driven by **commercial preparation activities for the ZUSDURI™ launch**[13](index=13&type=chunk) - Higher R&D expenses were mainly due to **increased manufacturing costs** and costs associated with the Phase 3 UTOPIA trial for UGN-103[12](index=12&type=chunk) [Financial Statements](index=2&type=section&id=Financial%20Statements) The condensed consolidated financial statements present detailed financial position and operational results for the three and six months ended June 30, 2025, compared to 2024 [Condensed Consolidated Statements of Operations](index=3&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) This statement details the company's revenues, expenses, and net loss for the three and six months ended June 30, 2025, and 2024 Condensed Consolidated Statements of Operations (in thousands, except per share data) | | Three months ended June 30, | Six months ended June 30, | | :--- | :--- | :--- | | | **2025** | **2024** | **2025** | **2024** | | **Revenue** | **$ 24,215** | **$ 21,848** | **$ 44,469** | **$ 40,629** | | Gross profit | 20,665 | 19,619 | 38,589 | 36,672 | | Total operating expenses | 62,113 | 45,458 | 116,951 | 88,251 | | **Operating loss** | **(41,448)** | **(25,839)** | **(78,362)** | **(51,579)** | | **Net loss** | **$ (49,940)** | **$ (33,403)** | **$ (93,783)** | **$ (65,689)** | | **Net loss per share** | **$ (1.05)** | **$ (0.82)** | **$ (1.97)** | **$ (1.69)** | [Selected Consolidated Balance Sheets](index=2&type=section&id=Selected%20Consolidated%20Balance%20Sheets) This statement provides a snapshot of the company's assets, liabilities, and equity as of June 30, 2025, and December 31, 2024 Selected Consolidated Balance Sheet Data (in thousands) | | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash, cash equivalents and marketable securities | $ 161,586 | $ 241,707 | | Total assets | $ 208,717 | $ 285,711 | | Total liabilities | $ 302,093 | $ 294,514 | [Full-Year 2025 Guidance](index=2&type=section&id=Full-Year%202025%20Guidance) UroGen reaffirmed its full-year 2025 guidance, projecting JELMYTO® net product revenues between $94 million and $98 million and total operating expenses from $215 million to $225 million Full-Year 2025 Financial Guidance | Metric | Guidance Range | | :--- | :--- | | JELMYTO Net Product Revenues | $94 - $98 million | | Total Operating Expenses | $215 - $225 million | | Non-cash Share-based Compensation | $11 - $14 million | - The revenue guidance implies an **8% to 12% year-over-year growth rate** for JELMYTO® over 2024 demand-driven sales[19](index=19&type=chunk) [Product and Company Information](index=3&type=section&id=Product%20and%20Company%20Information) This section provides detailed information on UroGen's commercial products, ZUSDURI™ and JELMYTO®, including their uses, mechanisms, and safety profiles, along with company overview [About ZUSDURI™](index=3&type=section&id=About%20ZUSDURI%E2%84%A2) ZUSDURI™ is an FDA-approved, mitomycin-based intravesical solution utilizing RTGel® technology for recurrent LG-IR-NMIBC, with detailed information on its use and safety - ZUSDURI™ is a prescription medicine for adults with recurrent LG-IR-NMIBC whose previous bladder surgery was not effective[25](index=25&type=chunk) - It utilizes UroGen's proprietary **RTGel® technology**, a sustained-release hydrogel, to enable non-surgical treatment of tumors in an outpatient setting[24](index=24&type=chunk) - Important safety information includes contraindication for patients with a perforated bladder and the need for effective contraception for both females and males during and after treatment[26](index=26&type=chunk)[27](index=27&type=chunk)[29](index=29&type=chunk) [About JELMYTO®](index=4&type=section&id=About%20JELMYTO%C2%AE) JELMYTO® is a mitomycin-containing reverse thermal gel approved for LG-UTUC, with details on its mechanism, approved use, and important safety information - JELMYTO® is a prescription medicine for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC)[34](index=34&type=chunk) - Its **reverse thermal gel technology** becomes a semi-solid at body temperature, allowing the drug to remain in the collecting system for **four to six hours** for sustained chemoablative therapy[33](index=33&type=chunk) - Serious side effects can include swelling and narrowing of the ureter (ureteric obstruction) and bone marrow problems leading to decreased blood cell counts[44](index=44&type=chunk) [About UroGen Pharma Ltd.](index=5&type=section&id=About%20UroGen%20Pharma%20Ltd.) UroGen is a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty cancers using its proprietary RTGel® platform, with two approved products - UroGen is a biotech company dedicated to developing and commercializing innovative solutions for urothelial and specialty cancers[42](index=42&type=chunk) - The company's proprietary **RTGel® platform** is a sustained-release, hydrogel-based technology designed to improve the therapeutic profiles of existing drugs for local therapy[42](index=42&type=chunk) [Other Information](index=2&type=section&id=Other%20Information) This section provides details on the conference call for Q2 results and includes cautionary forward-looking statements regarding potential risks and uncertainties [Conference Call & Webcast Information](index=2&type=section&id=Conference%20Call%20%26%20Webcast%20Information) UroGen management hosted a conference call and webcast on August 7, 2025, to discuss financial results and provide a business update - A live conference call and webcast were held on the day of the earnings release to review financial results and provide a general business update[20](index=20&type=chunk) [Forward-Looking Statements](index=5&type=section&id=Forward-Looking%20Statements) This section contains cautionary forward-looking statements, highlighting various risks and uncertainties that could cause actual results to differ materially from projections - The press release includes forward-looking statements regarding the market opportunity for ZUSDURI, pipeline progress, financial guidance, and the potential of its RTGel technology[43](index=43&type=chunk) - These statements are subject to numerous risks and uncertainties, including clinical results, regulatory approval, commercialization challenges, competition, and market acceptance[43](index=43&type=chunk)

Exhibit 99.1 Montauk Renewables Announces Second Quarter 2025 Results PITTSBURGH, PENNSYLVANIA – August 6, 2025—Montauk Renewables, Inc. ("Montauk" or "the Company") (NASDAQ: MNTK), a renewable energy company specializing in the management, recovery, and conversion of biogas into renewable natural gas ("RNG"), today announced financial results for the second quarter ended June 30, 2025. Second Quarter Highlights: In the second quarter of 2025, we successfully completed the construction and commissioning of ...

Exhibit 99.1 News Release Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights – Announced positive top-line data from the open-label extension MESA trial of sevasemten in participants with Becker muscular dystrophy who previously completed ARCH and CANYON studies – – Announced encouraging top-line data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy – – Advanced the Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyo ...